Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)

Launched by YONSEI UNIVERSITY · Jul 7, 2015

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients ≥ 19 years old
• • Patients who received new generation sirolimus-eluting (Osiro®) stent implantation for treating ACS
• • Patients without significant clinical events such as MI, stent thrombosis or revascularization until 3 months after PCI
• • Provision of informed consent
• Exclusion Criteria:
• • Age \> 80 years
• • Increased risk of bleeding, anemia, thrombocytopenia
• • A need for oral anticoagulation therapy
• • Pregnant women or women with potential childbearing
• • Life expectancy \< 1 year
• • Patients who treated with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir, or atazanavir)
• • Patients who had history of intracranial hemorrhage
• • Moderate to severe hepatic dysfunction
• • Increased risk of bradycardia-related symptom (Guidance and reference)